INVESTOR PRESENTATION Data as of or for the period ended September 30, 2025 unless otherwise noted z Forward-Looking Statements This presentation may contain forward-looking statements with respect to Fulton Financial Corporation's (the "Corporation" or "Fulton") financial condition, results of operations and business. Do not unduly rely on forward-looking statements. Forward-looking statements can be identified by the use of words such as "may," "should," "will," "could," "estimates," "predicts," "potentia ...

3rd Quarter 2025 Financial Review October 22, 2025 Forward-Looking Statements These materials contain certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"), Section 27A of the Securities Act of 1933 and Rule 175 promulgated thereunder, and Section 21E of the Securities Exchange Act of 1934 and Rule 3b-6 promulgated thereunder, notwithstanding that such statements are not specifically identified as such. In addition, certain statements may ...

Financial Performance Highlights - Net revenue for 3Q25 reached $1429 million, with Year-To-Date (YTD) revenue at $3969 million[4] - GAAP net earnings for 3Q25 were $202 million ($1.84 EPS), and non-GAAP net earnings were $214 million ($1.95 EPS)[4] - Year-to-date GAAP net earnings reached $391 million ($3.56 EPS), while non-GAAP net earnings were $454 million ($4.13 EPS)[4] - The company's book value per share is $49.74, with a tangible book value per share of $34.99[4] Global Wealth Management (GWM) - GWM net revenue for 3Q25 was $907 million, a 10% increase year-over-year[15] - Transactional revenue within GWM reached $203 million, up 5% year-over-year[20] - Asset management revenue in GWM was $431 million, a 13% increase year-over-year[20] - Total client assets in GWM reached $544010 million, a 10% increase year-over-year[22] Institutional Group - Institutional Group revenue for 3Q25 was $500 million, a 34% increase year-over-year[15] - Advisory revenue within the Institutional Group was $179 million, up 31% year-over-year[36] - Capital raising revenue in the Institutional Group was $138 million, a 38% increase year-over-year[36] Expenses and Capital - Compensation expense for 3Q25 was $829 million, a 17% increase year-over-year[43] - Non-compensation expense for 3Q25 was $298 million, a 7% increase year-over-year[43]

Financial Performance - Revenue decreased by 5% year-over-year to $1.4 billion[8] - Segment profit increased by 2% year-over-year to $310 million[8] - Adjusted EPS increased by 4% year-over-year to $6.98[8] - Operating cash flow was $301 million, a decrease of $151 million year-over-year[8] Segment Results - Home Comfort Solutions revenue decreased by 12% to $913 million[18], and segment profit decreased to $203 million[18] - Building Climate Solutions revenue increased by 10% to $514 million[23], and segment profit increased to $134 million[23] Guidance and Outlook - Full year adjusted EPS guidance is $22.75 - $23.25[8] - 2025 Capital Expenditures are expected to be approximately $150 million[34] - Net Debt to Adjusted EBITDA ratio is 0.8x[8] Strategic Initiatives - The company is focused on ROI-focused investments for growth[32] - Share repurchases year-to-date totaled approximately $350 million[33] - The company acquired Duro Dyne and Supco for approximately $550 million[10]

INVESTOR PRESENTATION Q3 2025 Earnings Call October 22, 2025 Forward-looking Statements and Additional Information This presentation contains forward-looking statements within the meaning of the federal securities laws relating to the proposed merger with PB Bankshares, Inc. ("PBBKˮ) by Norwood Financial Corp. ("Norwoodˮ or "NWFLˮ), the integration of PBBK with NWFL, the combination of their businesses and projected or pro forma financial information and metrics. All statements other than statements of hist ...

OCTOBER 202 5 Agree Realty Overview (NYSE: ADC) NET LEASE REIT FOCUSED ON THE ACQUISITION & DEVELOPMENT OF HIGH-QUALITY RETAIL PROPERTIES OUR COMPANY Founded in 1971 by Executive Chairman, Richard Agree Public on the NYSE since 1994 $12.2 billion(1) retail net lease REIT headquartered in Royal Oak, Michigan 2,603 retail properties totaling approximately 53.7 million square feet in all 50 states Investment grade issuer ratings of A- from Fitch, Baa1 from Moody's, and BBB+ from S&P RETHINK RETAIL Capitalize o ...

Financial Highlights - Adjusted Diluted EPS grew by 22% due to record revenue performance[9] - Quarterly revenue surpassed $2 billion, up 11% year-over-year[12] - Adjusted Operating Margin expanded 510bps to 529%[12] - MCO revenue growth increased to be in the high-single-digit percent range[12] - Adjusted Diluted EPS is up 17% at the midpoint, for a range of $1450 to $1475[12] - Free Cash Flow is approximately $25 billion[43] Moody's Investors Service (MIS) - MIS revenue reached a record high of $11 billion[9] - MIS rated issuance guidance increased to the mid-single-digit percent range[40] - Refinancing walls approximately doubled since 2018, reaching $52 trillion in September 2025[13, 14] - Year-over-year increase of 6% since previous study; stock of forward maturities remains robust, exceeding $5 trillion funding deep currents[15] - Adjusted Operating Margin increased 560 bps to 652%[26] Moody's Analytics (MA) - MA delivered 400bps of margin expansion in Q3[16] - ARR grew by 8% versus the prior year, reaching $34 billion[12] - Decision Solutions ARR is up 10%[9] - Recurring revenue accounts for 96% of total revenue[17]

Financial Performance - Net income reached $71.9 million, a 5% increase quarter-over-quarter[4] - Net Interest Margin (NIM) expanded by 0.07% to 3.00% from 2.93% in the previous quarter, and up 22 bps from Q3 2024[4,5] - Annualized Return on Assets (ROA) improved to 0.82%, and Return on Equity (ROE) improved to 9.5%[4] - Cost of deposits decreased by 0.09% to 2.38% from 2.47%, with a spot Annual Percentage Yield (APY) of 2.31% at September 30[4] Deposits - Average Non-interest-bearing Demand Deposit Accounts (NIDDA) increased by $210 million quarter-over-quarter and $741 million year-over-year[4] - NIDDA declined by $488 million quarter-over-quarter due to normal seasonality[4,5] - NIDDA accounted for 30% of total deposits as of September 30, 2025[4,5] - Non-interest DDA was $8,625 million, a decrease of $488 million from the previous quarter but an increase of $990 million year-over-year[5] Loans and Asset Quality - Total loans decreased by $231 million, with lower yielding and non-core residential, franchise, equipment, and municipal finance down an aggregate of $245 million[4,5] - Period-end Core Commercial & Industrial (C&I) and Commercial Real Estate (CRE) loans were $15,090 million, a decrease of $69 million from the previous quarter[5] - Non-performing assets to total assets ratio was 1.10%[5] - Allowance for Credit Losses (ACL) to total loans ratio was 0.93%[5] Capital - Common Equity Tier 1 (CET1) ratio was 12.5%[4,5] - Tangible book value per share is now $39.27, an 8% year-over-year growth[4]

Innovent's Strategic Goals - Innovent aims to become a Global Premier Biopharma by 2027 and China's Top Biopharma by 2030[8] - The company plans to have ≥5 pipeline assets in global MRCT Phase 3 by 2030[8, 10] Takeda Collaboration - Innovent and Takeda have a strategic collaboration with a total deal size of up to $114 billion[20] - The collaboration includes $11 billion in cash upfront at a 20% premium and $100 million in equity investment[26] - Milestone payments could reach up to $102 billion[26] Takeda's Global Presence - Takeda has approximately 50000 employees and a presence in approximately 80 countries & regions[28] - Takeda's FY24 revenue was approximately $306 billion, with 44% from the U S, 29% from Europe & Canada, 12% from Japan, and 4% from China[28] Pipeline Development - IBI363 (PD-1/IL-2 α-bias) and IBI343 (CLDN182 ADC) are in global Phase 3 development[11, 40] - IBI3001 (EGFR/B7H3 ADC) is in global Phase 1 development[11, 40] IBI363 Clinical Data - IBI363 has shown promising ORR (Objective Response Rate) and mPFS (median Progression-Free Survival) in IO-resistant sqNSCLC, MSS colorectal cancer, and melanoma[50] - Over 1200 patients have been treated with IBI363 across multiple solid tumors[48] IBI343 Clinical Data - IBI343 has demonstrated clinical benefits in PDAC (Pancreatic Ductal Adenocarcinoma) and GC (Gastric Cancer), with lower GI toxicity AEs[62, 66] - In CLDN182+ GC, IBI343 showed significantly prolonged OS (Overall Survival) benefit compared to SoC (Standard of Care)[66]

Earnings Presentation Third Quarter 2025 October 22, 2025 Cautionary Note Regarding Forward Looking Statements | Non-GAAP Disclosures This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements reflect the current views of the Company's management with respect to, among other things, future events and the Company's financial performance. These statements are often, but not always, made through ...